Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
Artemis Investment Management LLP Has $17.38 Million Stake in BioXcel Therapeutics Inc (NASDAQ:BTAI)
08:20am, Tuesday, 28'th Apr 2020
Artemis Investment Management LLP trimmed its position in BioXcel Therapeutics Inc (NASDAQ:BTAI) by 26.7% in the first quarter, according to the company in its most recent Form 13F filing with the Sec
BioXcel Therapeutics (NASDAQ:BTAI) Upgraded to "Strong-Buy" at BidaskClub
06:32am, Saturday, 25'th Apr 2020
BidaskClub upgraded shares of BioXcel Therapeutics (NASDAQ:BTAI) from a buy rating to a strong-buy rating in a research note published on Tuesday, BidAskClub reports. Several other research firms also
Head-To-Head Review: Crinetics Pharmaceuticals (NASDAQ:CRNX) and BioXcel Therapeutics (NASDAQ:BTAI)
06:28am, Saturday, 25'th Apr 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the st
How BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Can Impact Your Portfolio Volatility
11:21am, Friday, 24'th Apr 2020
If you're interested in BioXcel Therapeutics, Inc. (NASDAQ:BTAI), then you might want to consider its beta (a measure...
BioXcel Therapeutics CEO Says Wearable Devices Are Another Tool To Combat Alzheimer's Agitation
04:03pm, Wednesday, 15'th Apr 2020
BioXcel Therapeutics (NASDAQ: BTAI) founder and CEO Dr. Mehta Vimal spoke with Benzinga about its BXCL-501 drug candidate for agitation in Alzheimer's patients —...
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals (MDGL) and CareDx (CDNA)
11:22am, Wednesday, 15'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
BioXcel Therapeutics Inc (NASDAQ:BTAI) Receives Average Recommendation of "Buy" from Brokerages
07:42am, Friday, 10'th Apr 2020
Shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) have earned an average recommendation of “Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Two equi
Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020
07:15pm, Monday, 06'th Apr 2020
NEW YORK, NY / ACCESSWIRE / April 6, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a fourth day of presentations as pa
Fly Intel: Top five analyst initiations ZM;BTAI;PROF;AEO;HBI;ESPR;KNSA
02:51pm, Wednesday, 01'st Apr 2020
Fly Intel: Top five analyst initiations ZM BTAI PROF AEO HBI ESPR KNSA
Oppenheimer sees 26% downside in Intuitive Surgical in premarket action
11:51am, Wednesday, 01'st Apr 2020
Apellis Pharmaceuticals (NASDAQ:APLS) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James.BioXcel Therapeutics (NASDAQ:BTAI) initiated with Buy rating and $45 (101% up
Biotech stocks have held up better than the broader market — and these five are potential winners
08:23pm, Tuesday, 24'th Mar 2020
Landmine No. 1: Smaller biotech companies short on cash will face a funding crunch if the stock market stays down. How to diffuse it: Favor biotech companies that just raised cash, or have enough on
Bioxcel Therapeutics (BTAI) Received its Third Buy in a Row
01:27pm, Thursday, 19'th Mar 2020
After Canaccord Genuity and BMO Capital gave Bioxcel Therapeutics (NASDAQ: BTAI) a Buy rating last month, the company received another Buy, this time from
Bioxcel Therapeutics (BTAI) Received its Third Buy in a Row
01:27pm, Thursday, 19'th Mar 2020
After Canaccord Genuity and BMO Capital gave Bioxcel Therapeutics (NASDAQ: BTAI) a Buy rating last month, the company received another
BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials
11:15am, Thursday, 19'th Mar 2020
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-o
